Indivior (NASDAQ:INDV) Announces Earnings Results

Indivior (NASDAQ:INDV) announced its quarterly earnings results on Thursday. The company reported $0.82 earnings per share for the quarter, beating analysts’ consensus estimates of $0.65 by $0.17, Zacks reports. The business had revenue of $358.00 million during the quarter, compared to analysts’ expectations of $305.62 million. Indivior had a net margin of 16.85% and a negative return on equity of 126.17%.

Here are the key takeaways from Indivior’s conference call:

• Indivior reported strong 2025 results with SUBLOCADE net revenue of $856M (up 13%), total net revenue of $1.24B (up 4%), and record adjusted EBITDA of $428M (up 20%) with notable margin improvement.
• Management gave 2026 guidance calling for accelerated momentum — mid-teens U.S. SUBLOCADE dispense growth, SUBLOCADE net revenue of $905M–$945M (~8% at midpoint), adjusted EBITDA of $535M–$575M (≈30% growth) and ~ $300M operating cash flow.
• The company completed organizational simplification and set a 2026 non-GAAP operating expense target of ≤$450M after taking $120M of restructuring charges in 2025 (≈$28M cash cost), which should improve leverage but involved upfront costs.
• Indivior strengthened its financial flexibility by paying the $295M DOJ obligation (eliminating a legacy liability), exiting 2025 with net leverage below 1x, and announcing a new $400M opportunistic share repurchase program while prioritizing debt management and commercial-stage M&A.
• Management warned of headwinds in 2026 that pressure total revenue at the midpoint — expected U.S. SUBOXONE Film pricing pressure, lower rest-of-world revenue after optimization, gross-to-net movements, and continued PERSERIS runoff.

Indivior Stock Performance

Shares of INDV opened at $32.72 on Friday. Indivior has a 1 year low of $8.34 and a 1 year high of $38.00. The stock has a market capitalization of $4.09 billion, a PE ratio of 19.95 and a beta of 0.80. The stock has a 50-day simple moving average of $34.55 and a 200-day simple moving average of $29.99.

Wall Street Analyst Weigh In

INDV has been the subject of several research reports. Craig Hallum reiterated a “buy” rating and issued a $41.00 target price on shares of Indivior in a report on Friday, October 31st. Morgan Stanley restated an “overweight” rating and set a $36.00 price target on shares of Indivior in a research report on Wednesday, December 3rd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Indivior in a research note on Wednesday, January 28th. Northland Securities set a $50.00 target price on Indivior in a research note on Tuesday, January 20th. Finally, HC Wainwright lifted their target price on Indivior from $35.00 to $48.00 and gave the company a “buy” rating in a research report on Monday, January 12th. Five investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $39.33.

Insider Buying and Selling at Indivior

In other news, Director Daniel A. Ninivaggi purchased 775 shares of the stock in a transaction that occurred on Monday, January 5th. The shares were acquired at an average price of $35.39 per share, for a total transaction of $27,427.25. Following the acquisition, the director directly owned 16,923 shares in the company, valued at approximately $598,904.97. The trade was a 4.80% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Mark Stejbach acquired 775 shares of Indivior stock in a transaction that occurred on Monday, January 5th. The shares were purchased at an average cost of $35.39 per share, with a total value of $27,427.25. Following the completion of the acquisition, the director owned 16,847 shares of the company’s stock, valued at $596,215.33. The trade was a 4.82% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last three months, insiders have bought 4,871 shares of company stock worth $172,385.

Institutional Trading of Indivior

A number of large investors have recently made changes to their positions in the stock. Quarry LP acquired a new position in Indivior in the 3rd quarter valued at about $26,000. Raymond James Financial Inc. purchased a new stake in shares of Indivior during the second quarter worth about $26,000. Financiere des Professionnels Fonds d investissement inc. raised its position in shares of Indivior by 26.6% in the fourth quarter. Financiere des Professionnels Fonds d investissement inc. now owns 11,917 shares of the company’s stock valued at $428,000 after buying an additional 2,502 shares during the last quarter. Swiss National Bank raised its position in shares of Indivior by 1.5% in the third quarter. Swiss National Bank now owns 193,431 shares of the company’s stock valued at $4,664,000 after buying an additional 2,900 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its position in Indivior by 1.7% during the fourth quarter. JPMorgan Chase & Co. now owns 211,208 shares of the company’s stock worth $7,578,000 after acquiring an additional 3,620 shares during the last quarter. Institutional investors and hedge funds own 60.33% of the company’s stock.

Indivior Company Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.